<DOC>
	<DOCNO>NCT00096226</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel carboplatin , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving paclitaxel carboplatin together radiation therapy surgery may shrink tumor remove . Giving chemotherapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give paclitaxel carboplatin together radiation therapy work treat patient undergo surgery stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel , Carboplatin , Radiation Therapy Treating Patients Who Are Undergoing Surgery Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine mediastinal node clearance rate patient stage IIIA IIIB non-small cell lung cancer treat neoadjuvant induction chemoradiotherapy comprise paclitaxel , carboplatin , high-dose radiotherapy follow surgical resection patient find resectable consolidative chemotherapy comprise paclitaxel carboplatin . - Determine rate complete pathological response patient treat regimen . - Determine feasibility surgical resection neoadjuvant induction chemoradiotherapy patient . - Determine disease-free overall survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This multicenter study . - Induction chemoradiotherapy : Patients undergo high-dose radiotherapy ( include total 6 fraction boost radiotherapy large field radiotherapy ) daily , 5 day week , approximately 7 week . Beginning first day radiotherapy , patient also receive paclitaxel IV 1 hour carboplatin IV 30 minute weekly 6 week . Patients reassess 4 week completion induction chemoradiotherapy . Patients resectable tumor undergo surgery within 2 week reassessment receive consolidation chemotherapy later 10 week surgery . Patients unresectable tumor proceed directly consolidation chemotherapy . - Consolidation chemotherapy : Patients receive paclitaxel IV 3 hour carboplatin IV 1 hour every 21 day 2 course . Patients follow 6 week , every 3 month 1 year , every 6 month 2-3 year , annually 4-5 year . PROJECTED ACCRUAL : A total 21-60 patient accrue study within 20 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Stage IIIA ( T13 , N2 ) IIIB ( N3 ) No clinical radiographic evidence supraclavicular lymph node involvement Pancoast tumor eligible Mediastinal nodal disease mediastinoscopy , thoracoscopy , Chamberlain procedure , transbronchial needle aspirate Nodes find positive mediastinoscopy define N2 disease Primary tumor must accessible highdose radiotherapy Measurable disease Potential candidate surgery No small cell lung cancer No bronchoalveolar carcinoma lobar multilobar involvement No malignant pleural effusion No distant metastases PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy At least 6 month Hematopoietic White blood cell count ( WBC ) ≥ 3,000/mm^3 Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 time ULN Albumin ≥ 3.0 g/dL Renal Creatinine ≤ 1.5 time ULN Cardiovascular No clinically evident superior vena cava syndrome Pulmonary Projected postoperative force expiratory volume ( FEV ) _1 &gt; 800 mL Other No know hypersensitivity Cremophor EL No unintentional weight loss ≥ 5 % within past 6 month No active serious infection No serious medical condition would preclude study participation No dementia significantly alter mental status would preclude give informed consent Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic chemotherapy No concurrent chemotherapy Endocrine therapy Concurrent steroid allow antiemetic prevention amelioration hypersensitivity reactions No concurrent hormonal therapy ( except megestrol appetite stimulation , estrogen , birth control pill ) Radiotherapy No prior radiotherapy thorax No concurrent intensitymodulated radiotherapy No concurrent postoperative thoracic radiotherapy Surgery Not specify Other No concurrent investigational therapy No concurrent amifostine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>